DRKS00031464招募中不适用
An international, prospective, observational cohort study to assess patient treatment satisfaction, patient-reported outcomes, effectiveness, and safety of a fixed-dose combination of Calcipotriene/Betamethasone Dipropionate PAD cream in the treatment of mild-to-moderate plaque psoriasis of the scalp in adults (PRO-SCALP) - PRO-SCALP Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Almirall S.A
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients with mild-to-moderate plaque psoriasis of the scalp (defined as PGA score of 2 or 3 at baseline) with or without involvement of the trunk and limbs, and who may or may not have been previously treated (treatment-naive patients) with other anti-psoriatic therapies; prescribed with Wynzora® treatment according to SmPC in routine clinical practice.
排除标准
- •Patients who are not eligible for treatment with Wynzora® in accordance with the approved product information.
研究者
相似试验
招募中
不适用
Study of infection zika virus in pregnancy and infantsVerifie the sequelae of zika virus infection in fetuses and infants born of mothers with had the infection during the pregnancy , particularly the involvement by microcephaly . This study aims to include healthy pregnant in the first trimester of pregnancy and follow them throughout the pregnancy and babies born of these being pregnant that were affected or not by the virus zikaB94.8C02.081.990C05.660.207.620RBR-73tqdfFundação Oswaldo Cruz
已完成
1 期
A multicentre, multinational prospective observational imaging biomarker study in early stage Huntington?s disease (HD) patients to assess imaging techniques and parameters able to support efficacy studies with SEN0014196 in HD patients during Phase II and III studiesISRCTN26193242Siena Biotech (Italy)60
尚未招募
不适用
A study to describe control of glucose in blood and quality of life for type 1 diabetic adult patientsCTRI/2018/05/013922Sanofi Synthelabo India Private Limited
进行中（未招募）
1 期
A study to find out whether some PAH patients may benefit by replacing their current phosphodiesterase-5 inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), with RiociguatPulmonary Arterial Hypertension (PAH)MedDRA version: 20.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2016-001067-36-GRBayer AG218
进行中（未招募）
1 期
A study to find out whether some PAH patients may benefit by replacing their current phosphodiesterase-5 inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), with RiociguatPulmonary Arterial Hypertension (PAH)MedDRA version: 20.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2016-001067-36-GBBayer AG218